COMMUNIQUÉS West-GlobeNewswire

OneMedNet Signs Global Pharmaceutical Intelligence Provider as Channel Partner, Extending Reach in Pharma Market
19/10/2026
Agreement with a leading global provider of pharmaceutical intelligence and data solutions expands distribution of OneMedNet’s first-party, direct-from-source multimodal Real-World Data; Strengthening its presence in a [...]
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
19/10/2026
Premier sponsorship of the HERmedicine and OncoMenopause Consortium ® program underscores Daré Bioscience's commitment to addressing unmet women’s health needs, including for women affected by breast cancer The program [...]
Beacon Biosignals Partners with Project Sleep to Shorten the Path to Diagnosis for People with Idiopathic Hypersomnia and Narcolepsy
19/10/2026
The partnership connects Beacon's AI-driven neurotechnology with the patient-led advocacy community, expanding access to diagnosis and bringing patient voices directly into clinical research BOSTON, Oct. 19, 2026 (GLOBE [...]
ProSomnus Announces Significant Scientific, Technical, and Advocacy Updates
19/10/2026
World-Renowned Sleep Medicine Leaders Join ProSomnus Medical Advisory Board, RPMO₂ Enhancements, Published FLOSAT Study Results, and Scientific Contributions at CHEST 2026 SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE [...]
RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
19/10/2026
ALISO VIEJO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and [...]
VIVUS Announces Positive Outcome of European Procedure to Extend QSIVA® (Phentermine/Topiramate MR) to Adolescents with Obesity
19/10/2026
— Landmark European approval will grant young patients and families an evidence-based therapy alongside lifestyle interventions AMSTERDAM, Oct. 19, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a [...]
Final Safety, Pharmacokinetic and Pharmacodynamic Data from COL-5671 Phase 1 Clinical Study Presented at UEGW
19/10/2026
COL-5671, a highly selective oral SIK3 inhibitor, demonstrated a favorable safety and pharmacokinetic (PK) profile Pharmacodynamic (PD) data indicate potent TNFα suppression at low doses , with even greater IL-23 [...]
TerrAscend to Host Third Quarter 2026 Earnings Conference Call
19/10/2026
TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. (the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis operator, today announced that it will host a scheduled conference call to [...]
XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
19/10/2026
Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival. Exploratory Subgroup analysis reveals [...]
23andMe Research Institute to Showcase Scientific Impact and Expanded Research Capabilities at ASHG 2026
19/10/2026
New research and capabilities highlight the power of more than 11 million consented research participants PALO ALTO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- At the American Society of Human Genetics (ASHG) 2026 Annual [...]
PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI
19/10/2026
Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows MENLO PARK, Calif. and DALLAS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB [...]
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
19/10/2026
SUNNYVALE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced [...]
Standard Dental Labs Signs $10 Million Equity Purchase Agreement with Twenty Four Capital
19/10/2026
Facility gives the Company discretion to access equity capital over time to support its Florida dental laboratory strategy ORLANDO, Fla., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Standard Dental Labs Inc. (OTCQB: TUTH) (“SDL” [...]
Phase 3 trial in China successfully confirms ACARIZAX® safety and efficacy in patients with house dust mite allergy
19/10/2026
Inside Information Phase 3 trial with ACARIZAX ® in Chinese participants met the primary objective and showed efficacy in line with previous trials, after only 24-28 weeks of treatment. ACARIZAX ® was shown to be safe [...]
FOXO TECHNOLOGIES INC.’S SUBSIDIARY, MYRTLE RECOVERY CENTERS, INC., ANNOUNCES EXPANSION OF ITS FLAGSHIP FACILITY AND FOCUS ON SUBSTANCE USE DISORDER PATIENTS WITH RELATED MEDICAL CARE NEEDS
19/10/2026
WEST PALM BEACH, FL, Oct. 19, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc.’s (OTC: FOXO) (“FOXO”) is pleased to announce that its subsidiary, Myrtle Recovery Centers, Inc. (“Myrtle”), recently received its license [...]
Leads Biolabs' Opamtistomig and LBL-034 Featured in Six Abstracts at 2026 ESMO Congress
19/10/2026
Three Studies Selected for Oral Presentation, Including a Late-Breaking Abstract; Data Highlight Durable Responses and Long-Term Survival Signals Across Immunologically Cold Tumors and Deep, Sustained Responses in [...]
Prime Minister Mark Carney Sends Greetings as Canada Lights Up Sea-foam Green for International Stuttering Awareness Day
19/10/2026
From Niagara Falls to the CN Tower, landmarks across Canada will shine sea-foam green on October 22 as Canadians call for greater understanding and acceptance of stuttering. TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
19/10/2026
COPENHAGEN, Denmark, October 19, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount [...]
Transactions under Novonesis’ share buyback program
19/10/2026
Please read the announcement in PDF Attachment 2026_22_Share_buyback

Pages